Hyperlipidemia malady

Wikipedia: Hyperlipidemia, hyperlipoproteinemia, or hyperlipidaemia (British English) involves abnormally elevated...⁴⁴ more...

MalaCards: Hyperlipidemia is related to familial combined hyperlipidemia and insulin resistance. An important gene associated with Hyperlipidemia is USF1 (upstream transcription factor 1), and among its related pathways are Statin Pathway, Pharmacodynamics and PPAR signaling pathway. The drugs fish oil and niacin and the compounds cholesterol ester and sterol have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and lung, and related mouse phenotypes are hematopoietic system and respiratory system.

hyperlipidemia 7 32 43

Disease types for hyperlipidemia family:

hyperlipidemia type 3

Diseases related to hyperlipidemia by text searches and GeneDecks gene sharing:

(show top 50)    (show all 901)

id	Related Disease	Score	Top Affiliating Genes
1	familial combined hyperlipidemia	38.6	APOA1, APOB, APOE, HMGCR
2	insulin resistance	35.3	LEPR, UCP2, IRS1, INS, PPARGC1A
3	familial hyperlipidemia	34.2	COG2, PCSK9, LPA, LPL, LIN9, LIPC
4	familial hypercholesterolemia	33.1	COG2, PCSK9, LPA, LPL, LIPC, LDLR
5	atherosclerosis	32.8	LCAT, CETP, ATHS, MMP3, FABP12, ALOX5
6	hypertension	32.5	GNB3, CYP11B2, NOS3, ACE, AGT, AGTR1
7	hypertriglyceridemia	32.4	LRP1, COG2, RBP4, SELP, SERPINE1, VLDLR
8	hepatitis	31.9	RBP4, SELP, XDH, FASLG, GPT, F2
9	hyperlipidemia type 3	31.7	COG2, LPA, LPL, LIPC, LDLR, CETP
10	familial hypertriglyceridemia	31.5	LPL, USF1, APOA1, APOA2, APOA5, APOB
11	ischemic heart disease	29.9	PIK3C2A, COG2, RETN, SELP, SERPINE1, LPA
12	lipodystrophy	29.8	LRP1, RETN, RBP4, SERPINE1, NAMPT, LPA
13	hyperlipoproteinemia type iii	29.5	COG2, SERPINE1, LPA, LPL, VCAM1, LIPC
14	hyperalphalipoproteinemia	29.4	LPL, LIPC, SCARB1, LDLR, LCAT, CETP
15	familial partial lipodystrophy	29.0	RETN, LEP, INS, APOE, TNF, PPARGC1A
16	combined hyperlipemia	29.0	LPL, LIPC, INS, APOA1, APOB
17	defective apolipoprotein b-100	29.0	LDLR, LCAT, APOB, APOE, HMGCR
18	alcoholism	28.9	GPT, HMGCR, ABCB7, TF, SLC17A5, CP
19	glucose intolerance	28.2	MTR, MTTP, CD79A, APOA4, APOB, PTH
20	hyperphosphatemia	28.1	BMP2, MGP, ALB, ALPP, PTH, SPP1
21	hypercholesterolemia	27.4	PIK3C2A, LRP1, COG2, RETN, VWF, PCSK9
22	vascular disease	27.0	LRP1, RETN, SGCB, VWF, SELP, SERPINC1
23	acute lymphocytic leukemia	26.8	SERPINC1, LPL, MTHFR, MTR, MPO, TNF
24	immunodeficiency	26.7	CD79A, CD55, ITGA4, INS, INSR, IL6
25	coronary heart disease	25.2	PIK3C2A, LRP1, COG2, RETN, VWF, PCSK9
26	proteinuria	24.4	PIK3C2A, COG2, VWF, RBP4, SELP, SERPINC1
27	obesity	24.2	PIK3CB, PIK3C2A, PIK3CG, LRP1, COG2, RETN
28	nephrotic syndrome	24.1	PIK3C2A, RETN, VWF, RBP4, SELP, SERPINC1
29	cholesterol	24.0	PIK3CB, PIK3C2A, PIK3CG, LRP1, COG2, RETN
30	type 2 diabetes mellitus	23.9	PIK3C2A, COG2, RETN, VWF, GCK, RBP4
31	hyperhomocysteinemia	23.9	VWF, SELP, SERPINC1, SERPINE1, LPA, VCAM1
32	hyperglycemia	23.2	PIK3CB, PIK3C2A, PIK3CG, COG2, RETN, VWF
33	diabetes mellitus	23.2	PIK3CB, PIK3C2A, PIK3CG, COG2, RETN, SGCB
34	diabetic retinopathy	21.8	PIK3CG, VWF, RBP4, SELP, SERPINE1, LPA
35	blindness	21.7	PIK3C2A, PIK3CG, COG2, VWF, PCDH15, RBP4
36	nephropathy	21.5	LRP1, COG2, RETN, VWF, GCK, RBP4
37	aortic aneurysm	20.9	PIK3C2A, RETN, VWF, SERPINC1, SERPINE1, LPA
38	homocysteine	20.5	PIK3C2A, COG2, RETN, VWF, GCK, SELP
39	osteoarthritis	20.4	PIK3CB, PIK3CG, RETN, SERPINB2, SERPINE1, NAMPT
40	lymphocytic leukemia	20.2	PIK3CG, SELP, SERPINC1, LPL, VCAM1, CHKA
41	multiple myeloma	19.9	PIK3CG, LRP1, VWF, RBP4, SELP, SERPINC1
42	schizophrenia	19.9	PIK3CB, PIK3CG, VLDLR, LPL, LMNB2, CLU
43	myeloma	19.5	PIK3CG, LRP1, VWF, RBP4, SELP, SERPINC1
44	ischemia	19.1	PIK3C2A, PIK3CG, COG2, RETN, SGCB, VWF
45	pancreatitis	17.3	PIK3CB, PIK3C2A, PIK3CG, LRP1, RETN, SGCB
46	leukemia	16.0	PIK3CB, PIK3C2A, PIK3CG, LRP1, COG2, RETN
47	lipoprotein lipase deficiency	15.0	LPA, LPL, LCAT, CETP, INS, APOA1
48	hypoalphalipoproteinemia	14.9	LPA, LPL, LIPC, LDLR, LCAT, CETP
49	tangier disease	14.8	SELP, LPA, LPL, CLU, LCAT, CETP
50	xanthomatosis	14.6	LPA, LPL, LDLR, INS, APOA1, APOB

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 coenzyme q10, fish oil, linolenic acid, niacin, niacin (as niacinamide), nicotinic acid

MalaCards organs/tissues related to hyperlipidemia:

²²

MGI Mouse Phenotypes related to hyperlipidemia:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system phenotype	MP:0005397	10.7	SERPINB2, MYO1E, ARNTL, MB, GP1BA, PTH
2	respiratory system phenotype	MP:0005388	10.7	SELP, LPL, LMNB2, LIF, LIPA, LEPR
3	endocrine/exocrine gland phenotype	MP:0005379	10.5	LIN9, LDLR, XDH, FASLG, GHR, PTH
4	other phenotype	MP:0005395	10.2	CLU, LEPR, LDLR, FN1, APOA2, APOA4
5	liver/biliary system phenotype	MP:0005370	10.1	RETN, PCSK9, GCK, SERPINC1, LPL, LIF
6	integument phenotype	MP:0010771	10.0	PIK3CG, SELP, LMNB2, LIF, LIPA, LIPE
7	embryogenesis phenotype	MP:0005380	9.5	PIK3CB, SERPINC1, LMNB2, LIN9, SCARB1, ITGA4
8	reproductive system phenotype	MP:0005389	9.3	RBP4, BMP2, LIN9, LIF, LIPE, LIPC
9	vision/eye phenotype	MP:0005391	9.0	PCDH15, RBP4, SELP, SERPINC1, VLDLR, LIF
10	limbs/digits/tail phenotype	MP:0005371	9.0	BMP2, SCD, LEP, CHKB, MTHFR, MMP9
11	immune system phenotype	MP:0005387	8.9	LRP1, SGCB, VWF, SELP, SERPINB2, LIN9
12	nervous system phenotype	MP:0003631	8.9	LRP1, VWF, PCDH15, SELP, SERPINC1, VLDLR
13	digestive/alimentary phenotype	MP:0005381	8.7	VWF, BMP2, LIN9, LIF, LIPA, LIPE
14	no phenotypic analysis	MP:0003012	8.7	VCAM1, MYO1E, LIN9, CLOCK, LEPR, LDLR
15	renal/urinary system phenotype	MP:0005367	8.6	GCK, SELP, MYO1E, LIPA, CLU, LEPR
16	adipose tissue phenotype	MP:0005375	8.4	PIK3C2A, LRP1, RETN, SERPINE1, VLDLR, LPL
17	behavior/neurological phenotype	MP:0005386	8.4	LRP1, PCDH15, SELP, VLDLR, LIF, LIPA
18	normal phenotype	MP:0002873	8.4	LRP1, RBP4, BMP2, USF1, LEPR, LDLR
19	growth/size phenotype	MP:0005378	8.3	PIK3CB, PIK3C2A, PIK3CG, LRP1, SGCB, PCDH15
20	mortality/aging	MP:0010768	7.6	PIK3CB, PIK3C2A, LRP1, VWF, GCK, SELP
21	tumorigenesis	MP:0002006	7.0	PIK3CB, SERPINE1, LEP, LEPR, MMP9, FN1
22	skeleton phenotype	MP:0005390	7.0	PIK3CG, LRP1, BMP2, LIF, LEP, LEPR
23	muscle phenotype	MP:0005369	5.7	PIK3CG, LRP1, SGCB, RBP4, SERPINB2, LPL
24	cellular phenotype	MP:0005384	4.9	PIK3CB, PIK3CG, VWF, RBP4, SELP, VLDLR
25	cardiovascular system phenotype	MP:0005385	4.9	PIK3CB, PIK3CG, LRP1, SGCB, VWF, RBP4
26	homeostasis/metabolism phenotype	MP:0005376	4.6	PIK3CB, PIK3C2A, PIK3CG, LRP1, RETN, VWF

Articles related to hyperlipidemia:

(show top 50)    (show all 475)

id	Title	Authors	Year	Affiliating Genes
1	FABP4 plasma levels are increased in familial combine d hyperlipidemia. (20388924)	CabrAc A.... Masana L.	2010	FABP4
2	Postprandial lipemia enhances the capacity of large H DL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways i n type IIB hyperlipidemia. (20713650)	Julia Z.... Guerin M.	2010	ABCG1, SCARB1
3	A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia. (19816713)	Huertas-Vazquez A.... Pajukanta P.	2010	PCDH15
4	Complex porcine model of atherosclerosis: induction o f early coronary lesions after long-term hyperlipidemia without sustained hyper glycemia. (19340354)	Artinger S.... Pels K.	2009	ST3GAL4
5	Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. (18417194)	KarA!sek D.... NovotnA1 D.	2009	VWF, PLAT, SERPINE1
6	Lipid profile, low-density lipoprotein oxidation and ceruloplasmin in the progeny of families with a positive history of cardiovascu lar diseases and/or hyperlipidemia. (19648144)	Makedou K.G.... Papageorgiou G.E.	2009	CP
7	Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. (18451330)	Gleissner C.A.... Ley K.	2008	AKR1B1
8	Apolipoprotein E Arg136 --> Cys mutation and hyperlipidemia in a large central European population sample. (18326082)	Hubacek J.A.... Bobak M.	2008	APOE
9	Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. (17931620)	Kostapanos M.S.... Elisaf M.S.	2008	NAMPT
10	Relationship between familial combined hyperlipidemia and insulin resistance. (19069677)	JackuliakovA! D.... KarA!sek D.	2008	APOB, INS, LIPC
11	HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. (18270459)	Guan J.Z.... Suda T.	2008	APOE, ABCA1, APOA1
12	Apolipoprotein B is associated with metabolic syndrome in Chinese families with familial combined hyperlipidemia, familial hypertriglyceridemia and familial hypercholesterolemia. (16828905)	Pei W.D.... Yang Y.J.	2007	APOB
13	A preliminary study of hyperlipidemia in Bangkok school children. (17153077)	Sirikulchayanonta C.... Srisorrachata S.	2006	COG2
14	The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion. (16822320)	Wung S.F.... Aouizerat B.E.	2006	LPL
15	Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. (16606335)	Mutoh M.... Wakabayashi K.	2006	LPL, PPARG, PPARA
16	Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. (16639078)	Castellani L.W.... Reynolds W.F.	2006	MPO
17	The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II (16161915)	Broncel M.... Kostka B.	2005	SERPINC1
18	Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. (16079929)	Kiortsis D.N.... Tselepis A.D.	2005	PLA2G7, PON1
19	The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. (12901521)	Ye P.... Ding X.	2003	APOE, APOB
20	Effects of adding fenofibrate (200 mg/day) to simvast atin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrom e. (12686335)	Vega G.L.... Grundy S.M.	2003	APOB
21	Dietary fats do not contribute to hyperlipidemia in children and adolescents with type 1 diabetes. (12716788)	Wiltshire E.J.... Couper J.J.	2003	APOB
22	Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. (12220969)	Rukkumani R.... Menon V.P.	2002	GGT1, ALPP
23	Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. (12118856)	Rodrigo E.... Arias M.	2002	APOE, APOC3
24	C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor gamma expression in adipose tissue of familial combined hyperlipidemia patients. (11979403)	Ylitalo K.... Taskinen M.R.	2002	PPARG, C3, LIPE
25	Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds. (11833052)	del Rincon Jarero J.P.... Rull J.A.	2002	APOB
26	Postprandial hyperlipidemia, small and dense LDL, HDL sub-fractions (11431575)	Braschi S.	2001	INS
27	HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. (10781641)	Winkler K.... MAorz W.	2000	HMGCR
28	Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. (10681408)	Allayee H.... Lusis A.J.	2000	ATHS
29	Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group. (11031398)	Vicari R.M.... Teutsch S.M.	2000	COG2
30	Cerivastatin-a new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor: effect of 0,2 mg dose in patients with primary hyperlipidemias (10515032)	Solov'eva E.I.u.... Kukharchuk V.V.	1999	HMGCR
31	Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. (10357835)	Groenendijk M.... Dallinga-Thie G.M.	1999	APOA1, INS, APOC3
32	Serum leptin is elevated out of proportion to the bod y mass index in adolescent females with familial combined hyperlipidemia (FCH). (9924643)	Jacobson M.S.... Frank G.R.	1999	LSL
33	Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril. (9737124)	Vongterapak S.... Himathongkam T.	1998	ACE, ALB
34	Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. (9781635)	Hubel C.A.... Roberts J.M.	1998	VCAM1
35	Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. (9475252)	Nozaki S.... Matsuzawa Y.	1997	CD79A
36	Moderate dose, three-drug therapy with niacin, lovast atin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/d l in patients with hyperlipidemia and coronary artery disease. (9230143)	Brown B.G.... Knopp R.H.	1997	INS
37	Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. (8956036)	Deeb S.S.... Brunzell J.D.	1996	LPL, APOA4
38	Effect of apolipoprotein E polymorphism on the serum lipid response to a hypolipidemic diet rich in monounsaturated fatty acids in patients with hypercholesterolemia and combined hyperlipidemia. (7825526)	ZambA^n D.... Campero I.	1995	APOE
39	Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. (7738184)	Reynisdottir S.... Arner P.	1995	LIPE, APOB
40	Comparison of gemfibrozil versus simvastatin in famil ial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoprot eins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. (7856526)	Bredie S.J.... Stalenhoef A.F.	1995	APOB
41	Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. (7604787)	Smit J.W.... Erkelens D.W.	1995	MB
42	Apolipoprotein E in hyperlipidemia. (8185134)	Walden C.C.... Hegele R.A.	1994	APOE
43	Probucol treatment of hyperlipidemia (7853723)	Koizumi J.	1994	CETP
44	Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. (7851275)	Inoue I.... Kawazu S.	1994	INS
45	Clinical evaluation of simvastatin in the treatment of hyperlipidemia (8194433)	Lu Z.L.	1993	APOB
46	Obese men with type IIB hyperlipidemia are insulin resistant. (8399084)	KarhapAoAo P.... Laakso M.	1993	INS
47	XbaI polymorphism of the apolipoprotein B gene in patients with hyperlipidemia and echo-Doppler evidence of arterial lesions. (8512457)	De Lorenzo F.... Cocozza S.	1993	APOB
48	A heterozygous mutation (the codon for Ser447----a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. (1731801)	Kobayashi J.... Yoshida S.	1992	LPL
49	Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls. (1902595)	Ho C.H.... Jap T.S.	1991	PLAT
50	Management of hyperlipidemia: goals for the prevention of atherosclerosis. (2208837)	Illingworth D.R.	1990	HMGCR

Genes related to hyperlipidemia according to GeneCards:

(show top 50)    (show all 207)

id	Symbol	Description	Score	GeneCards Section Context
1	USF1	upstream transcription factor 1	11.1	Publications, Summaries
2	HYPLIP2	hyperlipidemia, combined, 2	11.1	Publications, Aliases & Descriptions
3	APOB	apolipoprotein B (including Ag(x) antigen)	11.0	Publications
4	LPL	lipoprotein lipase	11.0	Publications
5	HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	11.0	Publications
6	APOA1	apolipoprotein A-I	11.0	Publications
7	APOE	apolipoprotein E	11.0	Publications
8	CETP	cholesteryl ester transfer protein, plasma	11.0	Publications
9	APOC3	apolipoprotein C-III	11.0	Publications
10	COG2	component of oligomeric golgi complex 2	11.0	Publications
11	APOA2	apolipoprotein A-II	11.0	Publications
12	APOA5	apolipoprotein A-V	11.0	Publications
13	LCAT	lecithin-cholesterol acyltransferase	11.0	Publications
14	LIPC	lipase, hepatic	11.0	Publications
15	LSL	Leptin, serum levels of	11.0	Publications
16	INS	insulin	11.0	Publications
17	LDLR	low density lipoprotein receptor	11.0	Publications
18	PPARA	peroxisome proliferator-activated receptor alpha	11.0	Publications
19	APOC2	apolipoprotein C-II	11.0	Publications
20	LIPE	lipase, hormone-sensitive	11.0	Publications
21	APOA4	apolipoprotein A-IV	11.0	Publications
22	C3	complement component 3	11.0	Publications
23	ADRB3	adrenoceptor beta 3	11.0	Publications
24	PON1	paraoxonase 1	11.0	Publications
25	ADIPOQ	adiponectin, C1Q and collagen domain containing	11.0	Publications
26	TXNIP	thioredoxin interacting protein	11.0	Publications
27	APOC1	apolipoprotein C-I	11.0	Publications
28	RXRG	retinoid X receptor, gamma	11.0	Publications
29	MTTP	microsomal triglyceride transfer protein	11.0	Publications
30	SCD	stearoyl-CoA desaturase (delta-9-desaturase)	11.0	Publications
31	UCP1	uncoupling protein 1 (mitochondrial, proton carrier)	11.0	Publications
32	FABP2	fatty acid binding protein 2, intestinal	11.0	Publications
33	PNLIP	pancreatic lipase	11.0
34	NR1H4	nuclear receptor subfamily 1, group H, member 4	11.0	Publications
35	ADD1	adducin 1 (alpha)	11.0	Publications
36	LPA	lipoprotein, Lp(a)	11.0	Publications
37	PPARG	peroxisome proliferator-activated receptor gamma	11.0	Publications
38	GPT	glutamic-pyruvate transaminase (alanine aminotransferase)	11.0	Publications
39	SERPINE1	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1	11.0	Publications
40	NR1H2	nuclear receptor subfamily 1, group H, member 2	11.0	Publications
41	LEPR	leptin receptor	11.0	Publications
42	LEP	leptin	11.0	Publications
43	ATHS	atherosclerosis susceptibility (lipoprotein associated)	11.0	Publications
44	MNDA	myeloid cell nuclear differentiation antigen	11.0	Publications
45	PNPLA2	patatin-like phospholipase domain containing 2	11.0	Publications
46	FADS3	fatty acid desaturase 3	11.0	Publications
47	SLC37A4	solute carrier family 37 (glucose-6-phosphate transporter), member 4	11.0
48	SOAT2	sterol O-acyltransferase 2	11.0	Publications
49	LPXN	leupaxin	11.0	Publications
50	MGP	matrix Gla protein	11.0	Publications

Pathways related to hyperlipidemia according to GeneDecks:

(show top 50)    (show all 75)

id	Pathway	Score	Top Affiliating Genes
1	Statin Pathway, Pharmacodynamics34	11.8	APOC2, APOC3, APOE, HMGCR, CYP7A1, PLTP
2	PPAR signaling pathway20	11.7	CD36, APOA1, APOA2, APOA5, APOC3, FABP4
3	Selected targets of HNF110	11.3	APOA1, ABCA1, INS, UCP2, LPA, CRP
4	Fat digestion and absorption20	11.2	ACAT2, APOA4, PNLIP, FABP2, APOB, APOA1
5	Metabolism of lipids and lipoproteins38	11.1	LPL, ALOX5, HSD11B1, AKR1B1, CYP7A1, CYP11B2
6	Selected targets of C/EBPbeta10	11.0	CETP, UCP3, VWF, FABP4, RETN, APOB
7	Adipocytokine signaling pathway20	10.8	RXRG, PPARA, G6PC, RXRA, CPT1B, PPARGC1A
8	Type II diabetes mellitus20	10.8	GCK, PIK3CB, ADIPOQ, INS, IRS1
9	Selected targets of C/EBPalpha10	10.7	SERPINC1, CD36, APOB, ALB, CETP, ADIPOQ
10	ACE Inhibitor Pathway, Pharmacodynamics34	10.7	AGTR1, AGTR2
11	Glucose / Energy Metabolism3	10.7	FASN, LIPE, SCD, IRS1, INSR, CAT
12	Aldosterone-regulated sodium reabsorption20	10.6	INS, PRKCB, HSD11B1, PIK3CB
13	Blood Coagulation Signaling Pathways37	10.3	VWF, SERPINC1, SERPINB2, SERPINE1, THBD, GP1BA
14	Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics34	10.3	AGTR1, ACE, NOS3, CYP11B2, AGT, AGTR2
15	Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics34	10.1	PIK3CB, INSR, INS, IRS1, GCK, PIK3CG
16	Adipocytokines & Insulin Signaling37	10.0	PRKCB, RBP4, RETN, PIK3CG, IRS1, ADIPOQ
17	RAR-Gamma-RXR-Alpha Degradation36	10.0	RXRA, CCL3, LIF, BMP2, CRABP2, CCL5
18	Insulin signaling pathway20	10.0	PPARGC1A, G6PC, SREBF1, PIK3CB, FASN, INSR
19	Complement and coagulation cascades20	9.9	CD55, FGA, F7, F2, PLAT, THBD
20	PGC1Alpha Pathway36	9.8	PPARA, CCL3, BMP2, INSR, IL1A, IL1B
21	LDL Oxidation in Atherogenesis36	9.7	TNF, CD36, IL1B, MPO, CCL3, VCAM1
22	PPAR Pathway36	9.7	IGF1, TNF, PPARG, PPARA, PPARD, RXRA
23	Pathways in cancer20	9.7	BMP2, PIK3CG, PIK3CB, MMP9, PPARD, RXRA
24	Malaria20	9.6	LRP1, VCAM1, SELP, TNF, CCL2, IL6
25	Selected targets of GCR-alpha10	9.6	LEP, UCP3, INS, INSR, THBD, NR3C1
26	Metabolic pathways20	9.4	CES1, CEL, XDH, MTR, FASN, MTHFR
27	African trypanosomiasis20	9.4	PRKCB, FASLG, APOA1, IL6, VCAM1, TNF
28	Amoebiasis20	9.4	FN1, SERPINB2, LAMB2, PRKCB, IL6, IL1B
29	Akt Signaling36	9.4	PDGFA, BMP2, LIF, IL6, CCL2, CCR5
30	Molecular Mechanisms of Cancer36	9.3	IL6, LAMB2, PDGFA, IRS1, CCL5, GNB3
31	Cytokine-cytokine receptor interaction20	9.2	FASLG, CCR5, CCL2, CCL5, IL6, IL1B
32	Immune response IL-1 signaling pathway10	9.1	CP, EDN1, NFKB1, IL6, IL1B, IL1A
33	Endothelin-1 Signaling Pathway36	9.1	FLT1, INSR, EDN1, CCL5, CCL3, IL6
34	Rheumatoid arthritis20	9.1	CCL5, IL6, CCL2, CCL3, IL1A, TNF
35	Immune response_IL-1 signaling pathway41	9.0	TNF, NFKB1, CP, IL6, IL1A, SERPINE1
36	all-trans-Retinoic Acid Signaling in Brain36	9.0	CCL5, ALOX5, TNF, BMP2, IL6, IL1B
37	Hematopoietic cell lineage20	9.0	CD59, ITGA4, TNF, CD36, CD55, GP1BA
38	MIF Mediated Glucocorticoid Regulation36	8.9	CCL3, CCL5, NFKB1, CCL2, IL6, IL1B
39	Chagas disease (American trypanosomiasis)20	8.7	NFKB1, IL1B, PIK3CB, TNF, C3, TNFRSF1A
40	Transcription_Role of VDR in regulation of genes involved in osteoporosis41	8.6	FASLG, APOE, IL6, IL1B, IGF1, PRKCB
41	Transcription Role of VDR in regulation of genes involved in osteoporosis10	8.6	IL6, RXRA, PRKCB, IL1A, APOE, NR3C1
42	MIF Regulation of Innate Immune Cells36	8.5	CCL2, IL1A, IL1B, LIF, BMP2, NFKB1
43	Rho Family GTPases36	8.1	NFKB1, CCL2, CCL3, IGF1, GNB3, CCL5
44	Influenza A20	8.0	PIK3CB, IL1A, IL1B, IL6, FASLG, CCL5
45	Antioxidant Action of Vitamin-C36	7.9	IGF1, FLT1, MYO1E, BMP2, LIF, PDGFA
46	Tec Kinases Signaling36	7.7	BMP2, ITGA4, FGFR4, IL6, CCL2, TNF
47	MAPK Family Pathway36	7.7	GNB3, IGF1, CCL5, FLT1, CCL2, TNF
48	JAK-STAT Pathway36	7.5	CCL3, CCL2, IL6, IL1B, IL1A, FGFR4
49	p38 Signaling36	7.5	NFKB1, CCL3, CCL5, LIF, CCR5, BMP2
50	ERK Signaling36	7.4	IL6, IL1B, PDGFA, NFKB1, SPP1, ESR2

Compounds related to hyperlipidemia according to GeneDecks:

(show top 50)    (show all 589)

id	Compound	Score	Top Affiliating Genes
1	cholesterol ester32	12.0	LRP1, COG2, LPA, LIPA, LIPE, LIPC
2	sterol32	11.9	LRP1, COG2, RETN, PCSK9, GCK, VLDLR
3	gemfibrozil32 9 9	13.7	PIK3C2A, COG2, LPA, LPL, LIPC, CHKA
4	ezetimibe32 9 9	13.3	COG2, SCARB1, CHKA, LDLR, MTTP, CETP
5	acetyl-coa32 18	12.2	GCK, LPL, LIPE, LIPC, USF1, CLOCK
6	lovastatin32 42 9 9	14.1	PIK3CB, PIK3C2A, LRP1, COG2, LPA, LPL
7	phospholipid32	10.9	PIK3CB, COG2, VWF, RBP4, VLDLR, LPL
8	glucose32	10.9	GP1BA, PTH, PNPLA2, AGL, NPHS1, SLC37A4
9	probucol32 9 9	12.7	LPL, VCAM1, LIPC, SCARB1, LDLR, LCAT
10	docosahexaenoic acid32 42 18	12.7	VCAM1, SCD, LCAT, CEL, CD59, FADS1
11	endotoxin32	10.6	RETN, SERPINB2, LIF, LEPR, CHKB, MNDA
12	acipimox32	10.5	LIPE, LEP, UCP3, CETP, INS, APOA1
13	27-hydroxycholesterol32	10.5	LDLR, HMGCR, HMGA1, CYP7A1, CYP11A1, CYP27A1
14	polyacrylamide32	10.5	RBP4, LPA, BMP2, LIPE, LEPR, CHKA
15	fenofibrate32 9 9	12.4	PIK3C2A, COG2, RETN, SELP, SERPINE1, LPA
16	rosuvastatin32 34 9 9	13.4	COG2, CHKB, LDLR, CETP, INS, IL6
17	vitamin-e32	10.4	PIK3C2A, COG2, RBP4, SERPINB2, LPA, VCAM1
18	cerivastatin32 9 9	12.4	PIK3C2A, COG2, SERPINE1, BMP2, CHKB, APOA1
19	uric acid32 18	11.4	PIK3C2A, RETN, RBP4, SERPINE1, LPA, LEP
20	sele32	10.3	SELP, LPL, VCAM1, LDLR, MTHFR, CETP
21	fenofibric acid32	10.3	APOC3, PPARA
22	tocopherol32	10.2	RBP4, LPL, SCARB1, LDLR, APOA1, APOB
23	carbamazepine32 34 9 9	13.2	COG2, CD36, IGFBP3, ALPP, CYP3A4, NR1H2
24	hyaluronic acid32 18	11.0	CD36, MMP3, FN1, FASLG, MB, GPT
25	metformin32 34 9 9	12.9	PIK3CG, COG2, RETN, VWF, GCK, SERPINE1
26	citrate32	9.8	PIK3C2A, GCK, SELP, LIPE, CHKA, CHKB
27	warfarin32 34 9 18 9	13.8	PIK3C2A, VWF, SELP, SERPINC1, LPA, MTHFR
28	lipid32	9.7	PIK3CB, PIK3C2A, PIK3CG, LRP1, COG2, RETN
29	androstenedione32 18	10.7	COG2, RBP4, SCARB1, LEP, LEPR, INS
30	forskolin32 42 9 9	12.5	RETN, SGCB, GCK, BMP2, LIF, LIPE
31	homocysteine32 18	10.5	PIK3C2A, COG2, RETN, VWF, SELP, SERPINC1
32	n acetylcysteine32	9.4	SGCB, VWF, SELP, SERPINC1, VCAM1, CLU
33	estradiol32 9 18 9	12.4	SERPINE1, LIF, SCARB1, LEPR, CHKA, CHKB
34	calcitriol32 42 9 18 9	13.4	PIK3CB, BMP2, LIF, CLU, CD36, MGP
35	azathioprine32 34 9 9	12.1	BMP2, LIF, CHKB, MTHFR, XDH, CD79A
36	histamine32 18	10.1	SGCB, VWF, SELP, VCAM1, MPO, CD79A
37	aprotinin32 9 9	11.0	LRP1, VWF, SELP, SERPINC1, SERPINB2, MMP9
38	procollagen32	9.0	BMP2, CD36, MMP3, MMP9, IL1A, IGFBP3
39	dihydrotestosterone32 9 18 9	11.7	SERPINE1, LPL, BMP2, CLU, LEP, CHKA
40	matrigel32	8.6	PIK3CG, LRP1, VWF, SERPINB2, SERPINE1, VCAM1
41	quercetin32 42 9 18 9	12.6	PIK3CB, PIK3C2A, PIK3CG, VCAM1, XDH, IRS1
42	wortmannin32 42	9.4	PIK3CB, PIK3C2A, PIK3CG, SGCB, VCAM1, BMP2
43	paraffin32	8.0	VWF, SERPINB2, VCAM1, LIF, CLU, LEP
44	estrogen32	7.8	PIK3CB, COG2, RETN, VWF, RBP4, SERPINC1
45	nitric oxide32 9 18 9	10.4	PIK3CB, COG2, RETN, SGCB, GCK, SELP
46	methotrexate32 34 42 9 9	11.2	PIK3C2A, SERPINE1, LEP, CHKB, MTRR, MTHFR
47	cyclosporin a32 42	7.9	PIK3C2A, PIK3CG, COG2, VWF, SELP, SERPINB2
48	dexamethasone32 42 34 9 9	10.4	LRP1, RETN, VWF, GCK, RBP4, SELP
49	genistein32 9 18 9	8.9	PIK3CG, SGCB, SELP, SERPINE1, LPL, VCAM1
50	retinoic acid32 42 18	6.8	PIK3CG, LRP1, VWF, GCK, RBP4, SELP

Cellular components related to hyperlipidemia according to GeneDecks:

(show all 14)

id	Name	GO ID	Score	Top Affiliating Genes
1	very-low-density lipoprotein particle	GO:034361	11.3	APOA1, APOA2, APOA4, APOA5, APOB, APOC1
2	high-density lipoprotein particle	GO:034364	11.3	APOA5, APOE, APOC1, APOA4, APOA2, APOF
3	chylomicron	GO:042627	11.2	LPL, APOA2, APOA4, APOA5, APOB, APOC1
4	low-density lipoprotein particle	GO:034362	11.0	APOE, APOC2, PLA2G7, APOF, LDLR, APOA5
5	spherical high-density lipoprotein particle	GO:034366	10.9	APOC3, PON1, APOA2, APOA1, CLU, APOC2
6	endoplasmic reticulum lumen	GO:005788	10.5	MTTP, CES1, INS, APOA1, APOA2, APOA4
7	intermediate-density lipoprotein particle	GO:034363	10.4	APOB, APOC2, APOC3, APOE
8	external side of plasma membrane	GO:009897	9.8	ABCG1, CD79A, LDLR, VCAM1, SELP, CD36
9	platelet alpha granule lumen	GO:031093	9.7	FGA, FN1, CLU, VWF, IGF1, ALB
10	cell surface	GO:009986	9.5	APOA4, CCR5, ALPP, GHR, TNFRSF1A, IL1A
11	integral to plasma membrane	GO:005887	9.4	FASLG, CCR5, GP1BA, GHR, TNF, TNFRSF1A
12	extracellular space	GO:005615	7.6	VCAM1, APOA1, APOA4, APOA5, APOB, APOC2
13	extracellular region	GO:005576	7.3	MMP9, RETN, INS, FGA, FGFR4, IL1A
14	plasma membrane	GO:005886	6.5	GP1BA, F7, F2, ALPP, CCR5, F11R

Biological processes related to hyperlipidemia according to GeneDecks:

(show top 50)    (show all 110)

id	Name	GO ID	Score	Top Affiliating Genes
1	lipoprotein metabolic process	GO:042157	11.8	CETP, APOA1, APOE, APOC3, APOC2, APOC1
2	lipid metabolic process	GO:006629	11.7	CD36, LPA, LPL, LIPE, CLU, APOC2
3	cholesterol homeostasis	GO:042632	11.6	SOAT2, SOAT1, G6PC, ABCG1, ABCA1, NR1H3
4	cholesterol metabolic process	GO:008203	11.6	LIPC, LEP, LEPR, LDLR, LCAT, CETP
5	high-density lipoprotein particle remodeling	GO:034375	11.3	ABCG1, LCAT, CETP, APOA1, APOA2, APOA4
6	cellular lipid metabolic process	GO:044255	11.3	FADS1, HMGCR, CPT1B, ACADM, ABCA1, RXRA
7	cholesterol efflux	GO:033344	11.3	APOA1, APOA2, APOA4, APOC1, APOC2, APOC3
8	reverse cholesterol transport	GO:043691	11.3	SCARB1, CLU, LIPC, LCAT, CETP, ABCG1
9	very-low-density lipoprotein particle remodeling	GO:034372	11.3	APOE, LCAT, CETP, APOA4, APOC2, LPL
10	phospholipid efflux	GO:033700	11.3	ABCG1, APOA2, APOA1, APOA4, APOC1, APOC2
11	triglyceride homeostasis	GO:070328	11.3	LPL, LIPC, APOA1, SCARB1, CETP, APOA5
12	triglyceride catabolic process	GO:019433	11.2	FABP4, PNPLA2, APOC3, APOB, APOA5, LIPC
13	negative regulation of macrophage derived foam cell differentiation	GO:010745	11.2	PPARA, NR1H2, CETP, ADIPOQ, ABCG1, ABCA1
14	positive regulation of cholesterol esterification	GO:010873	11.2	APOA2, APOA1, AGTR1, APOA4, APOC1, APOE
15	positive regulation of cholesterol efflux	GO:010875	11.1	LRP1, APOE, NR1H3, ADIPOQ, NR1H2, PON1
16	triglyceride metabolic process	GO:006641	11.1	CAT, APOE, APOA5, APOC1, APOC3, G6PC
17	positive regulation of fatty acid biosynthetic process	GO:045723	11.0	APOA4, APOC2, NR1H2, AGT, NR1H3, APOA5
18	cholesterol transport	GO:030301	11.0	CD36, LDLR, LCAT, APOB, APOA1, CETP
19	brown fat cell differentiation	GO:050873	11.0	FABP4, MB, ADRB1, PPARG, RGS2, UCP1
20	negative regulation of cholesterol storage	GO:010887	11.0	ABCA1, PPARG, PPARA, NR1H2, NR1H3, ABCG1
21	low-density lipoprotein particle remodeling	GO:034374	10.9	APOB, APOA2, MPO, CETP, PLA2G7, ABCG1
22	positive regulation of cellular protein metabolic process	GO:032270	10.9	ADIPOQ, AGTR1, AGT, NR1H3, NR1H2, INS
23	glucose homeostasis	GO:042593	10.8	ADIPOQ, G6PC, CYP11B1, FGFR4, GCK, PPARG
24	chylomicron remnant clearance	GO:034382	10.8	APOE, APOC2, APOC1, APOC3, LIPC
25	lipid transport	GO:006869	10.7	OSBPL10, PLTP, CHKA, CETP, APOA4, APOF
26	high-density lipoprotein particle clearance	GO:034384	10.7	APOA1, APOA2, APOC2, APOE, SCARB1
27	cellular response to insulin stimulus	GO:032869	10.7	PPARG, IRS1, GCK, VLDLR, USF1, ADIPOQ
28	lipoprotein transport	GO:042953	10.6	PPARG, APOC2, APOB, CD36, LRP1, PRKCB
29	steroid metabolic process	GO:008202	10.5	STAR, CYP24A1, G6PC, PNLIP, CYP11B1, CYP11A1
30	response to nutrient	GO:007584	10.4	ALOX5, HMGCR, PPARG, AGL, ADIPOQ, UCP3
31	positive regulation of macrophage derived foam cell differentiation	GO:010744	10.2	AGT, NFKB1, APOB, CD36, LPL, AGTR1
32	platelet degranulation	GO:002576	10.1	VWF, FN1, CD36, CLU, SERPINE1, SELP
33	small molecule metabolic process	GO:044281	10.0	PIK3C2A, CHKB, CHKA, SCARB1, LIPE, LPL
34	negative regulation of lipid catabolic process	GO:050995	9.9	INS, IL1B, APOA2, APOC1, APOC3, TNF
35	response to glucocorticoid stimulus	GO:051384	9.8	CCL2, CCL5, TNF, PLAT, RXRA, AGL
36	G-protein coupled receptor signaling pathway	GO:007186	9.8	APOE, AGT, CCR5, GNB3, ABCA1, EDN1
37	aging	GO:007568	9.7	ADRB1, ADRB3, AGT, CCL2, RXRA, VCAM1
38	monocyte chemotaxis	GO:002548	9.6	CCL2, FLT1, PTPRO, CCL5, CCL3, IL6
39	cellular response to interleukin-1	GO:071347	9.6	EDN1, MMP9, NFKB1, CYP11A1, CCL5, CCL3
40	positive regulation of MAPK cascade	GO:043410	9.5	INS, LIF, CD36, FLT1, LEP, ADRB3
41	positive regulation of glycogen biosynthetic process	GO:045725	9.5	IRS1, IGF1, GCK, INSR, INS, PTH
42	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.4	PDGFA, PPARD, CAT, CCL5, IGF1, INS
43	positive regulation of apoptotic process	GO:043065	9.2	AGTR2, CLU, BMP2, MNDA, MMP9, IL1B
44	response to hypoxia	GO:001666	9.1	PPARA, CRP, PLAT, NOS3, EDN1, ADIPOQ
45	positive regulation of angiogenesis	GO:045766	9.0	C3, PRKCB, NOS3, TNFRSF1A, CCL5, IL1B
46	platelet activation	GO:030168	8.5	VWF, PRKCB, TF, PDGFA, SELP, SERPINE1
47	inflammatory response	GO:006954	8.3	PIK3CG, SELP, BMP2, LIPA, IL1B, IL6
48	blood coagulation	GO:007596	8.2	VWF, SELP, SERPINC1, SERPINB2, SERPINE1, CLU
49	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.2	PPARGC1A, SREBF2, SREBF1, PTH, TNFRSF1A, TNF
50	anti-apoptosis	GO:006916	8.1	IL1B, EEF1A2, NR3C1, TNF, F7, IGF1

Molecular functions related to hyperlipidemia according to GeneDecks:

(show all 29)

id	Name	GO ID	Score	Top Affiliating Genes
1	lipid binding	GO:008289	11.3	CETP, APOA2, APOA4, APOA5, APOC2, APOE
2	cholesterol binding	GO:015485	11.2	ABCG1, NR1H3, CETP, APOA1, APOA2, APOC3
3	cholesterol transporter activity	GO:017127	11.2	ABCG1, STAR, APOB, APOA4, APOA2, APOA1
4	phosphatidylcholine-sterol O-acyltransferase activator activity	GO:060228	11.1	APOC1, APOA4, APOA2, APOA1, APOE
5	triglyceride lipase activity	GO:004806	11.1	PNPLA2, PNLIP, LIPE, CEL, LIPC, LPL
6	lipid transporter activity	GO:005319	11.1	MTTP, CETP, APOE, APOA4, APOA2, APOF
7	phosphatidylcholine binding	GO:031210	11.1	APOA4, CETP, APOA2, APOC1, APOA5
8	lipase inhibitor activity	GO:055102	11.0	APOC3, APOC2, APOA2, APOC1
9	protein heterodimerization activity	GO:046982	11.0	USF1, BMP2, APOA2, APOB, APOE, NR1H3
10	ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity	GO:004879	10.9	PPARD, RXRA, PPARA, NR1H2, PPARG, ESR2
11	apolipoprotein binding	GO:034185	10.9	LRP1, PCSK9, VLDLR, LPA, LIPC, SCARB1
12	retinoid X receptor binding	GO:046965	10.8	HMGA1, PPARG, NR1H3, NR1H4, NR1H2
13	retinyl-palmitate esterase activity	GO:050253	10.8	LIPC, PNPLA2, PNLIP, CES1, CEL
14	eukaryotic cell surface binding	GO:043499	10.7	ANXA5, APOA4, FGA, SELP, PDGFA, ADIPOQ
15	low-density lipoprotein particle binding	GO:030169	10.7	CRP, CD36, SCARB1, LIPC, PCSK9
16	phospholipid binding	GO:005543	10.5	APOC3, ANXA5, PLA2G7, ABCA1, APOB, ABCG1
17	high-density lipoprotein particle binding	GO:008035	10.5	SCARB1, CD36, APOA1, APOA2
18	heparin binding	GO:008201	10.5	APOB, CCL2, APOE, SELP, SERPINC1, LPA
19	drug binding	GO:008144	10.5	CHKA, ALB, PPARG, ADRB1, PPARD, ACE
20	fatty acid binding	GO:005504	10.3	APOC1, FABP4, FABP2, ALB, PPARD
21	protein homodimerization activity	GO:042803	10.1	NR3C1, NFKB1, BMP2, PDGFA, SHBG, USF1
22	steroid hormone receptor activity	GO:003707	10.1	NR1H4, ESR1, NR1H2, RXRA, RXRG, PPARD
23	receptor binding	GO:005102	10.0	LPL, BMP2, LIF, FGA, ADIPOQ, C3
24	hormone activity	GO:005179	10.0	LEP, IGF1, PTH, EDN1, AGT, ADIPOQ
25	iron ion binding	GO:005506	9.9	SCD, NOS3, CYP11B1, FADS3, FADS1, CYP27A1
26	heme binding	GO:020037	9.6	CYP7A1, CYP11B1, CYP11A1, CYP24A1, CYP3A4, NOS3
27	cytokine activity	GO:005125	9.6	IL6, NAMPT, BMP2, LIF, IL1A, IL1B
28	enzyme binding	GO:019899	9.2	CYP3A4, SLPI, APOB, RXRA, PPARG, HMGA1
29	protein binding	GO:005515	5.7	CCR5, ANGPTL4, FASLG, FASN, BMP2, CCL3